All GLP-1 Drugs Compared: Ozempic, Wegovy, Mounjaro, Zepbound & More

GLP-1 receptor agonists have transformed the landscape of weight management and metabolic health. With multiple medications now available — each with different active ingredients, dosing schedules, and FDA-approved indications — understanding how they compare is more important than ever. This guide breaks down the major GLP-1 drugs currently on the market to help you understand the key differences.

What Are GLP-1 Receptor Agonists?

GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medications that mimic the GLP-1 hormone naturally produced in your intestines. This hormone plays several important roles: it stimulates insulin secretion, inhibits glucagon release, slows gastric emptying, and acts on brain receptors to reduce appetite and promote feelings of fullness.

Originally developed for type 2 diabetes, GLP-1 medications have also demonstrated significant weight loss benefits in clinical trials, leading to FDA approvals specifically for chronic weight management.

Semaglutide-Based Medications

Ozempic® (Semaglutide 0.5 mg, 1 mg, 2 mg)

FDA-approved for: Type 2 diabetes; cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease.

How it works: Once-weekly subcutaneous injection. Dosing starts at 0.25 mg and escalates to maintenance doses of 0.5 mg, 1 mg, or 2 mg.

Key trial data: The SUSTAIN clinical trial program demonstrated significant improvements in blood sugar control (HbA1c reduction) and moderate weight loss as a secondary benefit. The SELECT trial showed cardiovascular benefits in at-risk patients.

Important note: While Ozempic is sometimes prescribed off-label for weight management, it is FDA-approved specifically for type 2 diabetes, not weight loss.

Wegovy® (Semaglutide 2.4 mg)

FDA-approved for: Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity; also approved for adolescents aged 12+ with obesity.

How it works: Once-weekly subcutaneous injection at a higher dose than Ozempic. Dose escalation over 16–20 weeks to the 2.4 mg maintenance dose.

Key trial data: The STEP clinical trial program reported that participants lost an average of approximately 15% of their body weight over 68 weeks compared to placebo. Individual results varied significantly.

Rybelsus® (Oral Semaglutide)

FDA-approved for: Type 2 diabetes.

How it works: Daily oral tablet (3 mg, 7 mg, or 14 mg). Must be taken on an empty stomach with a small sip of water, at least 30 minutes before other food, beverages, or medications.

Key consideration: Oral bioavailability of semaglutide is relatively low, which is why the oral doses don't directly compare to injectable doses. It is currently FDA-approved for diabetes management only.

Tirzepatide-Based Medications

Mounjaro® (Tirzepatide — for Diabetes)

FDA-approved for: Type 2 diabetes.

How it works: Once-weekly subcutaneous injection. Tirzepatide is a dual GIP/GLP-1 receptor agonist — meaning it activates both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, which may provide additive metabolic benefits.

Key trial data: The SURPASS program showed robust HbA1c reductions and significant weight loss compared to other diabetes medications including semaglutide.

Zepbound® (Tirzepatide — for Weight Management)

FDA-approved for: Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity.

How it works: Same active ingredient as Mounjaro but approved at weight management-specific doses. Once-weekly subcutaneous injection with dose escalation.

Key trial data: The SURMOUNT program reported that participants lost an average of approximately 18–22% of body weight at the highest doses, making it one of the most effective anti-obesity medications studied to date. Individual results varied.

Liraglutide-Based Medications

Saxenda® (Liraglutide 3.0 mg)

FDA-approved for: Chronic weight management in adults with obesity or overweight with comorbidity; also approved for adolescents aged 12+ with obesity.

How it works: Daily subcutaneous injection (not weekly like semaglutide or tirzepatide). Dose escalation over approximately 5 weeks to the 3.0 mg maintenance dose.

Key trial data: The SCALE program showed average weight loss of approximately 5–8% of body weight, which is less than what was observed with semaglutide or tirzepatide in their respective trials.

Victoza® (Liraglutide 1.8 mg)

FDA-approved for: Type 2 diabetes.

How it works: Daily subcutaneous injection at a lower dose than Saxenda. FDA-approved for blood sugar management rather than weight loss.

How Do GLP-1 Drugs Compare?

Here's a high-level comparison of key factors:

• Dosing frequency: Semaglutide (injectable) and tirzepatide are once-weekly; liraglutide and oral semaglutide are daily.
• Weight loss efficacy: Based on published trial data, tirzepatide (Zepbound) showed the highest average weight loss, followed by semaglutide (Wegovy), then liraglutide (Saxenda). Direct head-to-head comparisons are limited.
• Side effect profiles: All GLP-1 drugs share similar GI side effects (nausea, diarrhea, constipation, vomiting). These tend to be most pronounced during dose escalation.
• Mechanism: Semaglutide and liraglutide are GLP-1-only agonists; tirzepatide is a dual GIP/GLP-1 agonist, which may account for some of its additional efficacy.
• Administration: Most are injectable; Rybelsus is the only currently available oral GLP-1.

Newer and Emerging GLP-1 Medications

The GLP-1 space is evolving rapidly. Several new medications are in various stages of development or regulatory review:

• Orforglipron: An investigational oral GLP-1 receptor agonist that does not require the fasting restrictions of Rybelsus. Clinical trials are ongoing.
• CagriSema: A combination of semaglutide and cagrilintide (an amylin analog) that is being studied in Phase 3 trials for weight management.
• Retatrutide: A triple agonist (GLP-1/GIP/glucagon) showing promising early-phase results for both weight loss and metabolic improvement.
• Survodutide: A dual GLP-1/glucagon receptor agonist being investigated for obesity and metabolic liver disease.

These medications are investigational and not yet available for clinical use, but they represent the next generation of metabolic therapies.

Choosing the Right GLP-1 Medication

The best GLP-1 medication for any individual depends on multiple factors:

• Primary treatment goal (diabetes management, weight loss, or both)
• Tolerance for injections vs. preference for oral medication
• Insurance coverage and cost considerations
• Medical history and contraindications
• Provider recommendations based on your specific health profile

A licensed provider can evaluate your complete medical history, current medications, and health goals to recommend the most appropriate option.

The Bottom Line

GLP-1 receptor agonists represent a significant advance in both diabetes care and weight management. While they share a common mechanism, meaningful differences in dosing, efficacy, and FDA-approved indications exist between the available options. Understanding these differences — and working with a qualified provider — is key to finding the right treatment for your individual needs.

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any treatment.